Genelux Corporation (GNLX)

Market Cap	112.91M -21.2%
Revenue (ttm)	8,000
Net Income	-32.15M
EPS	-0.86
Shares Out	44.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,463
Open	2.480
Previous Close	2.480
Day's Range	2.427 - 2.525
52-Week Range	1.988 - 8.535
Beta	0.13
Analysts	Strong Buy
Price Target	19.80 (+685.71%)
Earnings Date	Mar 19, 2026

About GNLX

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2023
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: GNLX
• Website: https://www.genelux.com

Financial Performance

In 2025, Genelux's revenue was $8,000, a change of 0.00% compared to the previous year's $8,000. Losses were -$32.15 million, 7.62% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price target is $19.8, which is an increase of 685.71% from the latest price.

Price Target

$19.8

(685.71% upside)

Analyst Consensus: Strong Buy